Novel treatment setup for urethral carcinoma radiotherapy: A complete response case report

Abstract Background Chronic facial pain is a serious condition affecting millions of people worldwide. The reasons for chronic facial pain vary, and currently, the methods of treating chronic facial pain are expensive, invasive, and, based on current findings, ineffective. The purpose of this study is to develop and test an effective, cost-friendly method to treat patients with chronic facial pain. This study will examine the effectiveness of a novel treatment of a patient suffering from trigeminal neuralgia. Case presentation A 70-year-old Thai female visited the advanced general dentistry clinic at the Faculty of Dentistry, Mahidol University, Bangkok, Thailand. She was suffering from facial pain on her left side and was diagnosed by a physician as having trigeminal neuralgia. She experienced a sharp shooting pain that was triggered by facial movements such as chewing, speaking, or brushing teeth, and touching certain areas of her face. Bouts of pain lasted from a few seconds to several minutes, and episodes of several attacks lasted days, weeks, months, or longer prior to her visit to the advanced general dentistry clinic at Mahidol University. Physician designed an occlusal equilibration appliance for treating the patient by inserting the appliance in the mouth for dental occlusal equilibration (deprogram). The patient used this appliance by placing it in the mouth continuously (day and night) and removed it only when eating. After using the appliance for 2 weeks, the patient appeared to feel and look better prior to taking medication and was able to eat normally. The patient was pain free after treatment for a duration of 9 months. However, after 9 months, the pain reoccurred and manifested itself. Conclusion This novel treatment of recurrent facial pain showed an improvement of the patient’s chronic facial pain and serves as evidence to being a novel method for treating those suffering from trigeminal neuralgia.

Download Full-text

Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report

Tumori Journal ◽

10.1177/03008916211027219 ◽

2021 ◽

pp. 030089162110272

Author(s):

Ginevra Lolli ◽

Beatrice Casadei ◽

Cinzia Pellegrini ◽

Lisa Argnani ◽

Federica Cocito ◽

...

Keyword(s):

Case Report ◽

T Cell ◽

Human Leukocyte ◽

Complete Response ◽

Unrelated Donor ◽

Phosphatidylinositol 3 Kinase ◽

Leukocyte Antigen ◽

Follicular Helper ◽

T Cell Lymphomas ◽

T Cell Malignancies

Objective: Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous T-cell malignancies representing 5%–10% of aggressive lymphomas. The prognosis is poor for patients with relapsed/refractory (R/R) disease, with a median overall survival of less than 6 months and no standardized treatments. We discuss the role of the phosphatidylinositol 3-kinase (PI3K) γδ inhibitor duvelisib as bridge to allotransplantation in a patient with R/R PTCL. Methods: Case report. Results: A 55-year-old woman diagnosed with relapsed nodal PTCL with T-follicular helper phenotype received PI3K γδ inhibitor duvelisib in the context of the phase II PRIMO clinical trial. After two cycles at a dose of 75 mg twice daily, the patient achieved complete response (CR), which was subsequently consolidated with human leukocyte antigen fully matched unrelated donor allotransplantation. No major toxicities were recorded during the duvelisib treatment period or during hospitalization for allotransplantation. At the latest follow-up, the patient was alive and still in CR 10 months posttransplant. Conclusions: Duvelisib should be further explored as a bridge to allotransplantation in patients with R/R PTCL, given the success and low toxicity in our patient.

Download Full-text

Pathological complete response after intraperitoneal paclitaxel and systemic combined chemotherapy in a patient with peritoneal metastases from gastric cancer: a case report

Surgical Case Reports ◽

10.1186/s40792-020-00818-9 ◽

2020 ◽

Vol 6 (1) ◽

Cited By ~ 1

Author(s):

Yoshiyuki Meguro ◽

Hironori Yamaguchi ◽

Joji Kitayama ◽

Rihito Kanamaru ◽

Shiro Matsumoto ◽

...

Keyword(s):

Gastric Cancer ◽

Case Report ◽

Pathological Complete Response ◽

Complete Response ◽

Peritoneal Metastases ◽

Combined Chemotherapy

Download Full-text

Re-use of erlotinib in a patient using osimertinib after erlotinib, case report

Journal of Oncology Pharmacy Practice ◽

10.1177/10781552211019108 ◽

2021 ◽

pp. 107815522110191

Author(s):

Pinar Gursoy

Keyword(s):

Lung Cancer ◽

Case Report ◽

Treatment Options ◽

Resistance Mutation ◽

Growth Factor Receptor ◽

Complete Response ◽

Egfr Mutations ◽

T790m Mutation ◽

Development Of Resistance ◽

Exon 19

Introduction Most patients with non-small-cell lung cancer tumors that have epidermal growth factor receptor (EGFR) mutations have deletion mutations in exon 19 or exon 21, or both.In recent years, targeted therapies in lung cancer have increased survival, but the development of resistance to these drugs poses a major problem. Thesubstitution of methionineforthreonine at position 790 (T790M) mutation,is primarily responsible for this resistance. However, after osimertinib used in T790M positivepatients treatment options are generally limited to chemotherapy. Case report We reported the efficacy of erlotinib, which we reapplied due to the disappearance of the resistance mutation after osimertinib in a 68-year-old patient using osimertinib after erlotinib. Management and outcome: In the patient using erlotinib due to exon 19 deletion when progression was observed and T790M positivity was detected, osimertinib treatment was initiated. However, when T790M was found to be negative with rebiopsy in progression after osimertinib, a complete response was achieved by restarting erlotinib. Discussion The strategy of restarting erlotinib treatment with negative T790M mutation detected in biopsies of patients with osimertinib resistance may be an acceptable treatment option.

Download Full-text

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature

Journal of Investigative Medicine High Impact Case Reports ◽

10.1177/2324709621992207 ◽

2021 ◽

Vol 9 ◽

pp. 232470962199220

Author(s):

Balraj Singh ◽

Parminder Kaur ◽

Michael Maroules

Keyword(s):

Abdominal Pain ◽

Case Report ◽

Disease Burden ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Hepatocellular Cancer ◽

Past Medical History ◽

Review Of Literature ◽

Novel Treatment ◽

Accelerated Growth

Immune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with immunotherapy. Limited literature is available regarding hyperprogression in hepatocellular cancer. We report a case of a 36-year-old male with no past medical history who presented with nausea, vomiting, and abdominal pain and was diagnosed with unresectable hepatocellular cancer and thereby started on atezolizumab and bevacizumab. The patient got only 1 cycle of treatment and unfortunately had hyperprogression of disease.

Download Full-text

Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report

International Journal of Surgery Case Reports ◽

10.1016/j.ijscr.2021.106161 ◽

2021 ◽

pp. 106161

Author(s):

Toshiaki Komo ◽

Takahisa Suzuki ◽

Hirofumi Tazawa ◽

Haruki Sada ◽

Hiroshi Morimoto ◽

...

Keyword(s):

Gastric Cancer ◽

Case Report ◽

Advanced Gastric Cancer ◽

Peritoneal Dissemination ◽

Complete Response ◽

Line Treatment ◽

Clinical Complete Response ◽

Third Line ◽

Third Line Treatment

Download Full-text

Changing the Prognosis of Metastatic Cervix Uteri Adenosquamous Carcinoma through a Multimodal Approach: A Case Report

Case Reports in Oncology ◽

10.1159/000511564 ◽

2020 ◽

Vol 13 (3) ◽

pp. 1545-1551

Author(s):

Mihai Teodor Georgescu ◽

Dragos Eugen Georgescu ◽

Teodor Florin Georgescu ◽

Luiza Georgia Serbanescu

Keyword(s):

Case Report ◽

Adenosquamous Carcinoma ◽

Treatment Approach ◽

Complete Response ◽

Team Work ◽

Cervix Uteri ◽

Multimodal Approach ◽

Rare Cancer ◽

Management Guidelines ◽

Cancer Subtypes

Adenocarcinoma and adenosquamous carcinoma (AS) are 2 rare histological types of cervix uteri cancer constituting almost 20% of all cervix cancers, leading to a lack in patient management guidelines. We report the case of a 32-year-old woman with an oligometastatic cervix AS for which a multimodal treatment approach was used. Despite the patient’s bad prognosis, a complete response was achieved, which further resulted in excellent local control and prolonged survival. This case report serves the purpose of encouraging multidisciplinary team work and out-of-the-box thinking that should result in an individualized treatment for rare cancer subtypes.

Download Full-text